Omexa Formulary to Invest ₹95 Crore in New Unit for Monoclonal Antibodies and Formulations.

Chennai-based Omexa Formulary Pvt Ltd has announced plans to establish a state-of-the-art manufacturing unit near Tindivanam, Tamil Nadu, dedicated to monoclonal antibodies and formulation products. The ₹95 crore facility will be set up on a 4-acre site within the TANSIDCO Industrial Park in Pellakuppam Village, approximately 130 km south of Chennai.

The plant will have an annual production capacity of 520 kg of monoclonal antibodies and 164,000 units of formulation products per month, according to documents filed for environmental clearance. The unit will focus on producing 30 monoclonal antibody products along with prefilled syringes, vials, and lyophilized vials. The project is expected to create employment opportunities for around 120 people.

Omexa aims to leverage its expertise in fermentation technology to manufacture affordable monoclonal antibodies for treating cancer and other diseases, catering to both domestic and global markets. Co-founders Nate Ramanathan, CEO, and Rajan Garg, MD and Chief Marketing Officer, emphasized the company's goal of reducing treatment costs while addressing the rising demand for biologics.

This initiative aligns with India’s “Make in India” program and the broader push for import substitution. With the active pharmaceutical ingredient (API) and intermediates sector growing at an annual rate of 12% over the past decade, the company anticipates sustained momentum over the next five to ten years.

Omexa also plans to capitalize on the expiry of several key biological product patents, enabling it to offer cost-effective alternatives to global markets. The project aims to support India’s vision of becoming a global leader in biological products while fostering local job creation and skill development in biotechnology.

The proposed unit marks a strategic move in meeting the increasing demand for monoclonal antibodies, which play a crucial role in cancer treatment and other therapeutic areas.

HBL